References
Schinzinger A: Über Carcinoma mammae. Verh Dtsch Ges Chir 18: 28, 1889.
Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 2: 104, 1896.
De Courmelles F: La radiothérapie combinée du sein et des ovaires contre les tumeurs du sein. CR Acad Sci (Paris) 174: 503, 1922.
Cole MP: Suppression of ovarian function in primary breast cancer.In APM Forrest and PB Kunkler (eds). Prognostic Factors in Breast Cancer. Livingstone, 1968, pp 146–156.
Nissen-Meyer R: Suppression of ovarian function in primary breast cancer.In APM Forrest and PB Kunkler (eds). Prognostic Factors in Breast Cancer. Livingstone, 1968, pp 139–145.
Ravdin RG, Lewison EF, Slack NH, Gardner B, State D, Fisher B: Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet 131: 1055–1064, 1970.
Nissen-Meyer R: Prophylactic endocrine treatment in carcinoma of the breast. Clin Radiol 15: 152–160, 1964.
Meakin JW, Allt WEC, Beale FA, Brown TC, Bush RS, Clark RM, Fitzpatrick PJ, Hawkins NV, Jenkin RDT, Pringle JF, Reid JG, Rider WD, Hayward JL, Bulbrook RD: Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. Canad Med Assoc J 120: 1221–1229, 1979.
Dao TL, Nemoto T, Chamberlain A, Bross I: Adrenalectomy with radical mastectomy in the treatment of high-risk breast cancer. Cancer 35: 478–482, 1975.
Prudente A: Postoperative prophylaxis of recurrent mammary cancer with testosterone propionate. Surg Gynecol Obstet 80: 575–592, 1945.
Bulbrook RD, Hayward JL: The possibility of predicting the response of patients with early breast cancer to subsequent endocrine ablation. Cancer Res 25: 1135–1139, 1965.
Hubay CA, Pearson OH, Marshall JS, Stellato TA, Rhodes RS, DeBanne SM, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL and 27 Participating Investigators: Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial. Breast Cancer Res Treat 1: 77–82, 1981.
Palshof T: Adjuvant endocrine therapy. Canad J Surg 24: 379–384, 1981.
Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotkin D, Bowman D, Sachs S, Wolter J, Frelick R, Desser R, LiCalzi N, Geggie P, Campbell T, Elias EG, Prager D, Koontz P, Volk H, Dimitrov N, Gardner B, Lerner H, Shibata H, and other NSABP investigators: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305: 1–11, 1981.
Baum M, Barnes DM, Brinkley D, Dossett JA, Ellis S, Holdaway IM, King RJB, Lea J, Leake R, McPherson K, Nicholson R, Patterson J, Richards D, Rubens RD, Smiddy FG, Stoll BA, Wilson AJ: UK multicentre adjuvant Nolvadex (tamoxifen) trial (in preparation).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rubens, R.D. Adjuvant endocrine therapy of breast cancer. Breast Cancer Res Tr 2, 407–410 (1982). https://doi.org/10.1007/BF01805884
Issue Date:
DOI: https://doi.org/10.1007/BF01805884